MAP2K7 and B-cell chronic lymphocytic leukemia: Such reprogramming might be an expected response of CLL cells in patients on ibrutinib therapy; similar reprogramming was observed in (AZD6244)-treated triple-negative breast cancer cells where kinobead analysis has demonstrated adaptive activation of receptor tyrosine kinases in response to MEK inhibition (13), and in other malignant cell systems and small molecule agents (40, 41).